Artizan’s world-class biobanking program with its sophisticated bioinformatics system enables our research team to examine microbial drivers in many different disease types. This leads to the creation of precision therapeutics that inhibit specific soluble microbial factors and arrest ongoing pathogenesis.
The company’s flagship biobanking program, IBD-BIOME, collected clinical data from over 1,500 proprietary longitudinal samples from nearly 300 inflammatory bowel disease (IBD) patients and 200 healthy controls and initial interrogation using our drug discovery platform and IgA-SEQ™ technology allowed us to identify three clinical drug candidates intended for treatment of IBD.